We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Medpace is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Medpace is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 5.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, MEDP has gained about 74.7% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This shows that Medpace is outperforming its peers so far this year.
Another stock in the Medical sector, Bayer Aktiengesellschaft (BAYRY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 62.5%.
Over the past three months, Bayer Aktiengesellschaft's consensus EPS estimate for the current year has increased 5.4%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Medpace belongs to the Medical Services industry, a group that includes 63 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, this group has gained an average of 5% so far this year, meaning that MEDP is performing better in terms of year-to-date returns.
Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 11-stock industry is ranked #169. The industry has moved +4.2% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Medpace and Bayer Aktiengesellschaft as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Medpace is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Medpace is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 5.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, MEDP has gained about 74.7% so far this year. Meanwhile, stocks in the Medical group have gained about 4.9% on average. This shows that Medpace is outperforming its peers so far this year.
Another stock in the Medical sector, Bayer Aktiengesellschaft (BAYRY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 62.5%.
Over the past three months, Bayer Aktiengesellschaft's consensus EPS estimate for the current year has increased 5.4%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Medpace belongs to the Medical Services industry, a group that includes 63 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, this group has gained an average of 5% so far this year, meaning that MEDP is performing better in terms of year-to-date returns.
Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 11-stock industry is ranked #169. The industry has moved +4.2% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Medpace and Bayer Aktiengesellschaft as they could maintain their solid performance.